Compare Abeona Therapeutics Inc (ABEO) vs New York Times Co (NYT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs New York Times Co — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while New York Times Co trades at $73.89 (market cap $11.93B). The key difference: New York Times Co is far larger — about 32× Abeona Therapeutics Inc's market cap, and New York Times Co pays a 1.25% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | NYT | |
|---|---|---|
Market Cap | $373.32M | $11.93B |
Sector | Health | Media |
52-Week High | $7.23 | $85.86 |
52-Week Low | $4.17 | $51.43 |
Enterprise Value | $228.22M | $11.33B |
Dividend Yield | — | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
The New York Times Company (NYT) trades at $73.72, showing modest daily movement. The stock exhibits a bullish technical trend with strong moving average signals. Fundamentally, the company demonstrates consistent revenue growth, expanding profit margins, and robust cash flow from operations. Recent quarterly earnings have consistently surpassed analyst expectations, reflecting operational strength. A dividend of $0.23 per share is scheduled for payment in July 2026.
The outlook for NYT is positive, supported by solid financial performance and a 'Buy' analyst consensus with a $78.00 price target, implying potential upside. Key opportunities include sustained digital subscription growth and margin expansion. Primary risks involve competitive pressures in the media landscape and broader economic sensitivity affecting advertising revenue. The stock presents a compelling case for investors seeking a stable, growing media company.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
